Paul D. Burgess - Jan 19, 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Title: Chief Business Development and Strategic Operations Officer
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Jan 19, 2024
Transactions value $
$0
Form type
4
Date filed
1/23/2024, 05:37 PM
Previous filing
Dec 21, 2023
Next filing
Aug 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Restricted Stock Units Award $0 +81.1K $0.00 81.1K Jan 19, 2024 Common Stock 81.1K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Title: Chief Business Development and Strategic Operations Officer